Research ArticleOriginal Article
Open Access

Comparison of bacteremic pneumonia caused by Escherichia coli and Klebsiella pneumoniae

A retrospective study

Fuxing Li, Junqi Zhu, Yunwei Zheng, Youling Fang, Longhua Hu and Jianqiu Xiong
Saudi Medical Journal March 2024, 45 (3) 241-251; DOI: https://doi.org/10.15537/smj.2024.45.3.20230428

References

  1. 1.↵
    1. Forstner C,
    2. Patchev V,
    3. Rohde G,
    4. Rupp J,
    5. Witzenrath M,
    6. Welte T, et al.
    Rate and predictors of bacteremia in Afebrile community-acquired pneumonia. Chest 2020; 157: 529-539.
    OpenUrl
  2. 2.↵
    1. Yin Y,
    2. Zhao C,
    3. Li H,
    4. Jin L,
    5. Wang Q,
    6. Wang R, et al.
    Clinical and microbiological characteristics of adults with hospital-acquired pneumonia: a 10-year prospective observational study in China. Eur J Clin Microbiol Infect Dis 2021; 40: 683-690.
    OpenUrl
  3. 3.↵
    1. Cillóniz C,
    2. Dominedò C,
    3. Torres A.
    Multidrug resistant gram-negative bacteria in community-acquired pneumonia. Crit Care 2019; 23: 79.
    OpenUrl
  4. 4.↵
    1. Amati F,
    2. Restrepo MI.
    Emerging resistance of gram negative pathogens in community-acquired pneumonia. Semin Respir Crit Care Med 2020; 41: 480-495.
    OpenUrl
  5. 5.↵
    1. Metlay JP,
    2. Waterer GW,
    3. Long AC,
    4. Anzueto A,
    5. Brozek J,
    6. Crothers K, et al.
    Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med 2019; 200: e45-e67.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Tamma PD,
    2. Aitken SL,
    3. Bonomo RA,
    4. Mathers AJ,
    5. van Duin D,
    6. Clancy CJ.
    Infectious diseases society of America 2022 guidance on the treatment of extended-spectrum β-lactamase producing enterobacterales (ESBL-E), carbapenem-resistant enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Clin Infect Dis 2022; 75: 187-212.
    OpenUrl
  7. 7.↵
    1. Chen IR,
    2. Lin SN,
    3. Wu XN,
    4. Chou SH,
    5. Wang FD,
    6. Lin YT.
    Clinical and microbiological characteristics of bacteremic pneumonia caused by Klebsiella pneumoniae. Front Cell Infect Microbiol 2022; 12: 903682.
    OpenUrl
  8. 8.↵
    1. Jean SS,
    2. Chang YC,
    3. Lin WC,
    4. Lee WS,
    5. Hsueh PR,
    6. Hsu CW. Epidemiology
    , treatment, and prevention of nosocomial bacterial pneumonia. J Clin Med 2020; 9: 275.
    OpenUrl
  9. 9.↵
    1. Weiss G.
    Nutrition and infection. Clin Microbiol Infect 2018; 24: 8-9.
    OpenUrlPubMed
  10. 10.↵
    1. John TM,
    2. Deshpande A,
    3. Brizendine K,
    4. Yu PC,
    5. Rothberg MB.
    Epidemiology and outcomes of community-acquired Escherichia coli pneumonia. Open Forum Infect Dis 2021; 9: ofab597.
    OpenUrl
  11. 11.
    1. Chen D,
    2. Zhang Y,
    3. Wu J,
    4. Li J,
    5. Chen H,
    6. Zhang X, et al.
    Analysis of hypervirulent Klebsiella pneumoniae and classic Klebsiella pneumoniae infections in a Chinese hospital. J Appl Microbiol 2022; 132: 3883-3890.
    OpenUrl
  12. 12.↵
    1. Li F,
    2. Zhu J,
    3. Hang Y,
    4. Chen Y,
    5. Gu S,
    6. Peng S, et al.
    Clinical characteristics and prognosis of hospital-acquired Klebsiella pneumoniae bacteremic pneumonia versus Escherichia coli bacteremic pneumonia: a retrospective comparative study. Infect Drug Resist 2023; 16: 4977-4994.
    OpenUrl
  13. 13.↵
    1. Olson G,
    2. Davis AM.
    Diagnosis and treatment of adults with community-acquired pneumonia. JAMA 2020; 323: 885-886.
    OpenUrl
  14. 14.↵
    1. Fernando SM,
    2. Tran A,
    3. Cheng W,
    4. Klompas M,
    5. Kyeremanteng K,
    6. Mehta S, et al.
    Diagnosis of ventilator-associated pneumonia in critically ill adult patients-a systematic review and meta-analysis. Intensive Care Med 2020; 46: 1170-1179.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Singer M,
    2. Deutschman CS,
    3. Seymour CW,
    4. Shankar-Hari M,
    5. Annane D,
    6. Bauer M, et al.
    The third international consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016; 315: 801-810.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Hachiya A,
    2. Karasawa M,
    3. Imaizumi T,
    4. Kato N,
    5. Katsuno T,
    6. Ishimoto T, et al.
    The ISN/RPS 2016 classification predicts renal prognosis in patients with first-onset class III/IV lupus nephritis. Sci Rep 2021; 11: 1525.
    OpenUrl
  17. 17.↵
    1. Humphries R,
    2. Bobenchik AM,
    3. Hindler JA,
    4. Schuetz AN.
    Overview of changes to the clinical and laboratory standards institute performance standards for antimicrobial susceptibility testing, M100, 31st edition. J Clin Microbiol 2021; 59: e0021321.
    OpenUrlCrossRef
  18. 18.
    1. Jain S,
    2. Self WH,
    3. Wunderink RG,
    4. Fakhran S,
    5. Balk R,
    6. Bramley AM, et al.
    Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med 2015; 373: 415-427.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Jain S,
    2. Pavia AT.
    Editorial commentary: the modern quest for the “Holy Grail” of pneumonia etiology. Clin Infect Dis 2016; 62: 826-828.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Chen SC,
    2. Wu WY,
    3. Yeh CH,
    4. Lai KC,
    5. Cheng KS,
    6. Jeng LB, et al.
    Comparison of Escherichia coli and Klebsiella pneumoniae liver abscesses. Am J Med Sci 2007; 334: 97-105.
    OpenUrlCrossRefPubMedWeb of Science
  21. 21.↵
    1. Shelat VG,
    2. Chia CL,
    3. Yeo CS,
    4. Qiao W,
    5. Woon W,
    6. Junnarkar SP.
    Pyogenic liver abscess: does Escherichia coli cause more adverse outcomes than Klebsiella pneumoniae? World J Surg 2015; 39: 2535-2542.
    OpenUrl
  22. 22.↵
    1. Scheuerman O,
    2. Schechner V,
    3. Carmeli Y,
    4. Gutiérrez-Gutiérrez B,
    5. Calbo E,
    6. Almirante B, et al.
    Comparison of predictors and mortality between bloodstream infections caused by ESBL-producing Escherichia coli and ESBL-producing Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2018; 39: 660-667.
    OpenUrlPubMed
  23. 23.↵
    1. Lin YT,
    2. Jeng YY,
    3. Chen TL,
    4. Fung CP.
    Bacteremic community-acquired pneumonia due to Klebsiella pneumoniae: clinical and microbiological characteristics in Taiwan, 2001-2008. BMC Infect Dis 2010; 10: 307.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Zhou C,
    2. Jin L,
    3. Wang Q,
    4. Wang X,
    5. Chen F,
    6. Gao Y, et al.
    Bloodstream infections caused by carbapenem-resistant enterobacterales: risk factors for mortality, antimicrobial therapy and treatment outcomes from a prospective multicenter study. Infect Drug Resist 2021; 14: 731-742.
    OpenUrl
  25. 25.↵
    1. Çopur Çiçek A,
    2. Ertürk A,
    3. Ejder N,
    4. Rakici E,
    5. Kostakoğlu U,
    6. Esen Yıldız İ, et al.
    Screening of antimicrobial resistance genes and epidemiological features in hospital and community-associated carbapenem-resistant Pseudomonas aeruginosa infections. Infect Drug Resist 2021; 14: 1517-1526.
    OpenUrl
  26. 26.↵
    1. Zhang X,
    2. Qu F,
    3. Jia W,
    4. Huang B,
    5. Shan B,
    6. Yu H, et al.
    Polymyxin resistance in carbapenem-resistant Enterobacteriaceae isolates from patients without polymyxin exposure: a multicentre study in China. Int J Antimicrob Agents 2021; 57: 106262.
    OpenUrl
  27. 27.↵
    1. Raro OHF,
    2. Collar GS,
    3. da Silva RMC,
    4. Vezzaro P,
    5. Mott MP,
    6. da Cunha GR, et al.
    Performance of polymyxin B agar-based tests among carbapenem-resistant Enterobacterales. Lett Appl Microbiol 2021; 72: 767-773.
    OpenUrl
  28. 28.↵
    1. Castanheira M,
    2. Doyle TB,
    3. Deshpande LM,
    4. Mendes RE,
    5. Sader HS.
    Activity of ceftazidime/avibactam, meropenem/vaborbactam and imipenem/relebactam against carbapenemase-negative carbapenem-resistant Enterobacterales isolates from US hospitals. Int J Antimicrob Agents 2021; 58: 106439.
    OpenUrl
  29. 29.↵
    1. Suda KJ,
    2. Traversa A,
    3. Patel U,
    4. Poggensee L,
    5. Fitzpatrick MA,
    6. Wilson GM, et al.
    Uptake in newly approved antibiotics prescribed to patients with carbapenem-resistant Enterobacterales (CRE). Infect Control Hosp Epidemiol 2023; 44: 674-677.
    OpenUrl
  30. 30.↵
    1. Gutiérrez-Gutiérrez B,
    2. Salamanca E,
    3. de Cueto M,
    4. Hsueh PR,
    5. Viale P,
    6. Paño-Pardo JR, et al.
    Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis 2017; 17: 726-734.
    OpenUrlPubMed
  31. 31.↵
    1. Meng H,
    2. Han L,
    3. Niu M,
    4. Xu L,
    5. Xu M,
    6. An Q, et al.
    Risk factors for mortality and outcomes in hematological malignancy patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infections. Infect Drug Resist 2022; 15: 4241-4251.
    OpenUrl
  32. 32.↵
    1. Montrucchio G,
    2. Costamagna A,
    3. Pierani T,
    4. Petitti A,
    5. Sales G,
    6. Pivetta E, et al.
    Bloodstream infections caused by carbapenem-resistant pathogens in intensive care units: risk factors analysis and proposal of a prognostic score. Pathogens 2022; 11: 718.
    OpenUrl
  33. 33.↵
    1. Kotov SV,
    2. Pulbere SA,
    3. Alesina NV,
    4. Boyarkin VS,
    5. Guspanov RI,
    6. Belomytsev SV, et al.
    [The problem of antibiotic resistance in patients with urinary tract infection]. Urologiia 2021: 5-12. [In Russian]
  34. 34.↵
    1. Paul M,
    2. Carrara E,
    3. Retamar P,
    4. Tängdén T,
    5. Bitterman R,
    6. Bonomo RA, et al.
    European society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect 2022; 28: 521-547.
    OpenUrl
  35. 35.↵
    1. Al-Hasan MN,
    2. Baddour LM.
    Resilience of the Pitt bacteremia score: 3 decades and counting. Clin Infect Dis 2020; 70: 1834-1836.
    OpenUrl
  36. 36.↵
    1. Henderson H,
    2. Luterbach CL,
    3. Cober E,
    4. Richter SS,
    5. Salata RA,
    6. Kalayjian RC, et al.
    The Pitt bacteremia score predicts mortality in nonbacteremic infections. Clin Infect Dis 2020; 70: 1826-1833.
    OpenUrl
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools
Bookmark this article

Jump to section

Keywords